Journal article
Transcriptomics, metabolomics, lipidomics, metabolic flux and mGWAS analyses of sphingolipid pathway highlights novel drugs for Alzheimer’s disease
Priyanka Baloni, Matthias Arnold, Herman Moreno, Kwangsik Nho, Gabi Kastenmüller, Karsten Suhre, Luna Buitrago, Gregory Louie, Alexandra Kueider‐Paisley, Andrew J Saykin, Kim Ekroos, Peter J Meikle, Kevin Huynh, Cory C Funk, Leroy Hood, Nathan D Price, Rebecca Baillie, Xianlin Han, Rima F Kaddurah‐Daouk
Alzheimer's & Dementia | Wiley | Published : 2021
DOI: 10.1002/alz.056152
Abstract
AbstractBackgroundAlzheimer’s disease (AD) related neurodegeneration has been correlated with metabolic dysfunction. Sphingomyelins (SM), a class of lipids found in the cell membranes especially myelin sheath, have been shown to be disrupted in AD and in other neurodegenerative diseases. Ceramides, the simplest of the sphingolipids, are known to be associated with Aβ production and inflammation. In order to characterize the SM pathway for its molecular links to AD pathogenesis we used complementary multi‐omics approach and identified targets that can be used for intervention.MethodIn this study we used post‐mortem brain transcriptome data of 1000 AD and cognitively normal individuals from RO..
View full abstract